M-C. Vekemans MD

Diagnosis and treatment of AL amyloidosis: Belgian guidelines

SUMMARY

Immunoglobulin light chain (AL) amyloidosis is a rare and serious disease due to the deposition of amyloid fibrils. In the past years, improvements have been made in the diagnosis, treatment and response criteria. Based on an extensive review of the recent literature on AL amyloidosis, we propose practical recommenddations that can be used by Belgian haematologists as a reference for daily practice. Management of other types of amyloidosis will not be covered by this review. Levels of evidence and grades of recommendations are based on previously published methods.¹ We recommend participation in clinical trials to gain knowledge in this evolving field.

(BELG J HEMATOL 2020;11(8):343-56)

Practical management of multiple myeloma: Update 2020

SUMMARY

With the introduction of immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal anti-bodies, major improvements have been achieved in the treatment and outcome of multiple myeloma (MM). Different treatment combinations are now in use and other therapies are being developed. This rapidly changing therapeutic landscape urges for an update on practical guidelines. Based on an extensive review of the recent literature, we propose recommendations on myeloma management, to be used by haematologists as a reference for daily practice.

(BELG J HEMATOL 2020;11(8):357-75)

Practical management of multiple myeloma: Update 2020

SUMMARY

With the introduction of immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies, major improvements have been achieved in the treatment and outcome of multiple myeloma (MM). Different treatment combinations are now in use and other therapies are being developed. This rapidly changing therapeutic landscape urges for an update on practical guidelines. Based on an extensive review of the recent literature, we propose recommendations on myeloma management, to be used by haematologists as a reference for daily practice.

(BELG J HEMATOL 2020;11(7):286-304)

Highlights of the EHA25 virtual congress

SUMMARY

For the first time, in the context of the COVID-19 pandemic, the annual congress of EHA was turned into a full virtual edition, focusing on haematological innovations and evidence-based knowledge of primary clinical evidence. We choose to report ten abstracts of clinical interest that may have a direct impact on our daily practice.

(BELG J HEMATOL 2020;11(5):197-202)

P.22 AL amyloidosis revealed by polyarthritis

P.33 Myeloma cast nephropathy leading to early kidney allograft dysfunction: a case report

P.27 IgM related AL amyloidosis: about 2 cases